secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001171843-26-003119
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Filana Therapeutics Q1 net loss $10.3M; cash $86.6M, clinical hold on TSC program remains
--------------------------------------------------------------------------------

- Net loss of $10.3M ($0.21 per share) vs $23.4M loss in Q1 2025.
- Cash and cash equivalents $86.6M at March 31, 2026; no debt.
- R&D expenses $4.5M, down 67% due to Alzheimer's program phase-out.
- Company still addressing FDA clinical hold for simufilam in TSC-related epilepsy.
- Preclinical data in Epilepsia showed simufilam attenuated seizure progression in TSC mouse model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/0001171843-26-003119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/f8k_050726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer